Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone

Summary It has been suggested that increase in delta sleep ratio (DSR), a marker for the relative distribution of slow wave activity (SWA) over night time, is associated with clinical response to antidepressant treatment. We examined this index and its relationship to rapid eye movement (REM) suppre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of sleep research 2009-09, Vol.18 (3), p.342-348
Hauptverfasser: ARGYROPOULOS, SPILIOS V., HICKS, JANE A., NASH, JOHN R., BELL, CAROLINE J., RICH, ANNE S., NUTT, DAVID J., WILSON, SUE
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 348
container_issue 3
container_start_page 342
container_title Journal of sleep research
container_volume 18
creator ARGYROPOULOS, SPILIOS V.
HICKS, JANE A.
NASH, JOHN R.
BELL, CAROLINE J.
RICH, ANNE S.
NUTT, DAVID J.
WILSON, SUE
description Summary It has been suggested that increase in delta sleep ratio (DSR), a marker for the relative distribution of slow wave activity (SWA) over night time, is associated with clinical response to antidepressant treatment. We examined this index and its relationship to rapid eye movement (REM) suppression before and during long‐term treatment with nefazodone, which does not suppress REM sleep, and paroxetine which does. The effect of serotonin (5‐HT2A) receptor blockade on the evolution of SWA during treatment was also investigated. In a double‐blind, randomised, parallel group, 8‐week study in 29 depressed patients, sleep electroencephalograms were performed at home at baseline, on night 3 and 10, and at 8 weeks of treatment with either paroxetine or nefazodone. SWA was automatically analysed and a modified DSR (mDSR) was derived, being the ratio of amount of SWA in the first 90 min of sleep to that in the second plus third 90‐min periods. At baseline, the pattern of SWA over night time was similar to other reports of depressed patients. mDSR improved over the course of treatment; there was no difference between remitters and non‐remitters but there was a significant drug effect and a significant drug × time effect with paroxetine patients having a much higher mDSR after treatment, regardless of clinical status. SWA and REM during antidepressant treatment appear to be interdependent and neither of them alone is likely to predict response to treatment. Higher mDSR did not predict therapeutic response. 5‐HT2A blockade by nefazodone does not increase SWA above normal levels.
doi_str_mv 10.1111/j.1365-2869.2008.00724.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67598351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67598351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3664-6bccb11d10c5c848ba0983e3deb38f3a0fb59727883776da389168d507d954953</originalsourceid><addsrcrecordid>eNqNkUtv1DAUhS1ERaeFv4C8YpfUjsePSGxQxVOVkFpYW45903qUxMF2OjOs-eFNyAi29cbW9XfP1T0HIUxJSedztSspE7yolKjLihBVEiKrbXl4gTb_Pl6iDalFVVBK-Dm6SGlHCJWc1a_QOa35tiZSbdCfW3A-5eibKfsw4NDi1IU93ptHwMZm_-jzca0CjNhN0Q_3eHwwsTc2dOHeW9PhHMHkHoa8kA7GCCktanufH_BoYjhA9gPgeQgeQl7rA7Tmd3BhgNforDVdgjen-xL9_PTxx_WX4ub756_XH24Ky4TYFqKxtqHUUWK5VVvVGFIrBsxBw1TLDGkbXstKKsWkFM4wVVOhHCfSLftydonerbpjDL8mSFn3PlnoOjNAmJIWks-CnM6gWkEbQ0oRWj1G35t41JToJQG904vRejFaLwnovwnow9z69jRjanpw_xtPls_A-xXY-w6OzxbW3-5u5wd7Au7yl70</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67598351</pqid></control><display><type>article</type><title>Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>Wiley Blackwell Single Titles</source><source>EZB Electronic Journals Library</source><creator>ARGYROPOULOS, SPILIOS V. ; HICKS, JANE A. ; NASH, JOHN R. ; BELL, CAROLINE J. ; RICH, ANNE S. ; NUTT, DAVID J. ; WILSON, SUE</creator><creatorcontrib>ARGYROPOULOS, SPILIOS V. ; HICKS, JANE A. ; NASH, JOHN R. ; BELL, CAROLINE J. ; RICH, ANNE S. ; NUTT, DAVID J. ; WILSON, SUE</creatorcontrib><description>Summary It has been suggested that increase in delta sleep ratio (DSR), a marker for the relative distribution of slow wave activity (SWA) over night time, is associated with clinical response to antidepressant treatment. We examined this index and its relationship to rapid eye movement (REM) suppression before and during long‐term treatment with nefazodone, which does not suppress REM sleep, and paroxetine which does. The effect of serotonin (5‐HT2A) receptor blockade on the evolution of SWA during treatment was also investigated. In a double‐blind, randomised, parallel group, 8‐week study in 29 depressed patients, sleep electroencephalograms were performed at home at baseline, on night 3 and 10, and at 8 weeks of treatment with either paroxetine or nefazodone. SWA was automatically analysed and a modified DSR (mDSR) was derived, being the ratio of amount of SWA in the first 90 min of sleep to that in the second plus third 90‐min periods. At baseline, the pattern of SWA over night time was similar to other reports of depressed patients. mDSR improved over the course of treatment; there was no difference between remitters and non‐remitters but there was a significant drug effect and a significant drug × time effect with paroxetine patients having a much higher mDSR after treatment, regardless of clinical status. SWA and REM during antidepressant treatment appear to be interdependent and neither of them alone is likely to predict response to treatment. Higher mDSR did not predict therapeutic response. 5‐HT2A blockade by nefazodone does not increase SWA above normal levels.</description><identifier>ISSN: 0962-1105</identifier><identifier>EISSN: 1365-2869</identifier><identifier>DOI: 10.1111/j.1365-2869.2008.00724.x</identifier><identifier>PMID: 19549078</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Affect - drug effects ; Algorithms ; Antidepressive Agents, Second-Generation - therapeutic use ; Delta Rhythm ; delta sleep ratio ; depression ; Depressive Disorder - diagnosis ; Depressive Disorder - drug therapy ; Depressive Disorder - psychology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Electroencephalography - drug effects ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Monitoring, Ambulatory ; nefazodone ; paroxetine ; Paroxetine - therapeutic use ; rapid eye movement ; Signal Processing, Computer-Assisted ; Sleep - drug effects ; Sleep, REM - drug effects ; slow wave activity ; Treatment Outcome ; Triazoles - therapeutic use</subject><ispartof>Journal of sleep research, 2009-09, Vol.18 (3), p.342-348</ispartof><rights>2009 European Sleep Research Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3664-6bccb11d10c5c848ba0983e3deb38f3a0fb59727883776da389168d507d954953</citedby><cites>FETCH-LOGICAL-c3664-6bccb11d10c5c848ba0983e3deb38f3a0fb59727883776da389168d507d954953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2869.2008.00724.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2869.2008.00724.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19549078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ARGYROPOULOS, SPILIOS V.</creatorcontrib><creatorcontrib>HICKS, JANE A.</creatorcontrib><creatorcontrib>NASH, JOHN R.</creatorcontrib><creatorcontrib>BELL, CAROLINE J.</creatorcontrib><creatorcontrib>RICH, ANNE S.</creatorcontrib><creatorcontrib>NUTT, DAVID J.</creatorcontrib><creatorcontrib>WILSON, SUE</creatorcontrib><title>Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone</title><title>Journal of sleep research</title><addtitle>J Sleep Res</addtitle><description>Summary It has been suggested that increase in delta sleep ratio (DSR), a marker for the relative distribution of slow wave activity (SWA) over night time, is associated with clinical response to antidepressant treatment. We examined this index and its relationship to rapid eye movement (REM) suppression before and during long‐term treatment with nefazodone, which does not suppress REM sleep, and paroxetine which does. The effect of serotonin (5‐HT2A) receptor blockade on the evolution of SWA during treatment was also investigated. In a double‐blind, randomised, parallel group, 8‐week study in 29 depressed patients, sleep electroencephalograms were performed at home at baseline, on night 3 and 10, and at 8 weeks of treatment with either paroxetine or nefazodone. SWA was automatically analysed and a modified DSR (mDSR) was derived, being the ratio of amount of SWA in the first 90 min of sleep to that in the second plus third 90‐min periods. At baseline, the pattern of SWA over night time was similar to other reports of depressed patients. mDSR improved over the course of treatment; there was no difference between remitters and non‐remitters but there was a significant drug effect and a significant drug × time effect with paroxetine patients having a much higher mDSR after treatment, regardless of clinical status. SWA and REM during antidepressant treatment appear to be interdependent and neither of them alone is likely to predict response to treatment. Higher mDSR did not predict therapeutic response. 5‐HT2A blockade by nefazodone does not increase SWA above normal levels.</description><subject>Adult</subject><subject>Affect - drug effects</subject><subject>Algorithms</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Delta Rhythm</subject><subject>delta sleep ratio</subject><subject>depression</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - psychology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Electroencephalography - drug effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monitoring, Ambulatory</subject><subject>nefazodone</subject><subject>paroxetine</subject><subject>Paroxetine - therapeutic use</subject><subject>rapid eye movement</subject><subject>Signal Processing, Computer-Assisted</subject><subject>Sleep - drug effects</subject><subject>Sleep, REM - drug effects</subject><subject>slow wave activity</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><issn>0962-1105</issn><issn>1365-2869</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAUhS1ERaeFv4C8YpfUjsePSGxQxVOVkFpYW45903qUxMF2OjOs-eFNyAi29cbW9XfP1T0HIUxJSedztSspE7yolKjLihBVEiKrbXl4gTb_Pl6iDalFVVBK-Dm6SGlHCJWc1a_QOa35tiZSbdCfW3A-5eibKfsw4NDi1IU93ptHwMZm_-jzca0CjNhN0Q_3eHwwsTc2dOHeW9PhHMHkHoa8kA7GCCktanufH_BoYjhA9gPgeQgeQl7rA7Tmd3BhgNforDVdgjen-xL9_PTxx_WX4ub756_XH24Ky4TYFqKxtqHUUWK5VVvVGFIrBsxBw1TLDGkbXstKKsWkFM4wVVOhHCfSLftydonerbpjDL8mSFn3PlnoOjNAmJIWks-CnM6gWkEbQ0oRWj1G35t41JToJQG904vRejFaLwnovwnow9z69jRjanpw_xtPls_A-xXY-w6OzxbW3-5u5wd7Au7yl70</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>ARGYROPOULOS, SPILIOS V.</creator><creator>HICKS, JANE A.</creator><creator>NASH, JOHN R.</creator><creator>BELL, CAROLINE J.</creator><creator>RICH, ANNE S.</creator><creator>NUTT, DAVID J.</creator><creator>WILSON, SUE</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200909</creationdate><title>Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone</title><author>ARGYROPOULOS, SPILIOS V. ; HICKS, JANE A. ; NASH, JOHN R. ; BELL, CAROLINE J. ; RICH, ANNE S. ; NUTT, DAVID J. ; WILSON, SUE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3664-6bccb11d10c5c848ba0983e3deb38f3a0fb59727883776da389168d507d954953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Affect - drug effects</topic><topic>Algorithms</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Delta Rhythm</topic><topic>delta sleep ratio</topic><topic>depression</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - psychology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Electroencephalography - drug effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monitoring, Ambulatory</topic><topic>nefazodone</topic><topic>paroxetine</topic><topic>Paroxetine - therapeutic use</topic><topic>rapid eye movement</topic><topic>Signal Processing, Computer-Assisted</topic><topic>Sleep - drug effects</topic><topic>Sleep, REM - drug effects</topic><topic>slow wave activity</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ARGYROPOULOS, SPILIOS V.</creatorcontrib><creatorcontrib>HICKS, JANE A.</creatorcontrib><creatorcontrib>NASH, JOHN R.</creatorcontrib><creatorcontrib>BELL, CAROLINE J.</creatorcontrib><creatorcontrib>RICH, ANNE S.</creatorcontrib><creatorcontrib>NUTT, DAVID J.</creatorcontrib><creatorcontrib>WILSON, SUE</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of sleep research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ARGYROPOULOS, SPILIOS V.</au><au>HICKS, JANE A.</au><au>NASH, JOHN R.</au><au>BELL, CAROLINE J.</au><au>RICH, ANNE S.</au><au>NUTT, DAVID J.</au><au>WILSON, SUE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone</atitle><jtitle>Journal of sleep research</jtitle><addtitle>J Sleep Res</addtitle><date>2009-09</date><risdate>2009</risdate><volume>18</volume><issue>3</issue><spage>342</spage><epage>348</epage><pages>342-348</pages><issn>0962-1105</issn><eissn>1365-2869</eissn><abstract>Summary It has been suggested that increase in delta sleep ratio (DSR), a marker for the relative distribution of slow wave activity (SWA) over night time, is associated with clinical response to antidepressant treatment. We examined this index and its relationship to rapid eye movement (REM) suppression before and during long‐term treatment with nefazodone, which does not suppress REM sleep, and paroxetine which does. The effect of serotonin (5‐HT2A) receptor blockade on the evolution of SWA during treatment was also investigated. In a double‐blind, randomised, parallel group, 8‐week study in 29 depressed patients, sleep electroencephalograms were performed at home at baseline, on night 3 and 10, and at 8 weeks of treatment with either paroxetine or nefazodone. SWA was automatically analysed and a modified DSR (mDSR) was derived, being the ratio of amount of SWA in the first 90 min of sleep to that in the second plus third 90‐min periods. At baseline, the pattern of SWA over night time was similar to other reports of depressed patients. mDSR improved over the course of treatment; there was no difference between remitters and non‐remitters but there was a significant drug effect and a significant drug × time effect with paroxetine patients having a much higher mDSR after treatment, regardless of clinical status. SWA and REM during antidepressant treatment appear to be interdependent and neither of them alone is likely to predict response to treatment. Higher mDSR did not predict therapeutic response. 5‐HT2A blockade by nefazodone does not increase SWA above normal levels.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19549078</pmid><doi>10.1111/j.1365-2869.2008.00724.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0962-1105
ispartof Journal of sleep research, 2009-09, Vol.18 (3), p.342-348
issn 0962-1105
1365-2869
language eng
recordid cdi_proquest_miscellaneous_67598351
source MEDLINE; Wiley Online Library Journals; Wiley Blackwell Single Titles; EZB Electronic Journals Library
subjects Adult
Affect - drug effects
Algorithms
Antidepressive Agents, Second-Generation - therapeutic use
Delta Rhythm
delta sleep ratio
depression
Depressive Disorder - diagnosis
Depressive Disorder - drug therapy
Depressive Disorder - psychology
Dose-Response Relationship, Drug
Double-Blind Method
Electroencephalography - drug effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Monitoring, Ambulatory
nefazodone
paroxetine
Paroxetine - therapeutic use
rapid eye movement
Signal Processing, Computer-Assisted
Sleep - drug effects
Sleep, REM - drug effects
slow wave activity
Treatment Outcome
Triazoles - therapeutic use
title Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T19%3A00%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Redistribution%20of%20slow%20wave%20activity%20of%20sleep%20during%20pharmacological%20treatment%20of%20depression%20with%20paroxetine%20but%20not%20with%20nefazodone&rft.jtitle=Journal%20of%20sleep%20research&rft.au=ARGYROPOULOS,%20SPILIOS%20V.&rft.date=2009-09&rft.volume=18&rft.issue=3&rft.spage=342&rft.epage=348&rft.pages=342-348&rft.issn=0962-1105&rft.eissn=1365-2869&rft_id=info:doi/10.1111/j.1365-2869.2008.00724.x&rft_dat=%3Cproquest_cross%3E67598351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67598351&rft_id=info:pmid/19549078&rfr_iscdi=true